Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: Importance of interdisciplinary communication to prevent treatment errors with complex medications

被引：47

作者：

Geist, Marcus J. P.

Egerer, Gerlinde

Burhenne, Juergen

Riedel, Klaus-Dieter

Mikus, Gerd

机构：

[1] Univ Heidelberg, Dept Internal Med 6, Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany

[2] Univ Heidelberg, Dept Internal Med 5, D-69120 Heidelberg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 09期

关键词：

D O I：

10.1128/AAC.00579-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：3455 / 3456

页数：2

共 4 条

[1]

*FDA ANT DRUGS ADV, 2001, BRIEF DOC VOR OR INT

[2] Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype [J].

Geist, Marcus J. P. ;

Egerer, Gerlinde ;

Burhenne, Juergen ;

Mikus, Gerd .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :3227-3228

[3] Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J].

Hyland, R ;

Jones, BC ;

Smith, DA .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :540-547

[4] Bioanalytical Method Validation—A Revisit with a Decade of Progress [J].

Vinod P. Shah ;

Kamal K. Midha ;

John W. A. Findlay ;

Howard M. Hill ;

James D. Hulse ;

Iain J. McGilveray ;

Gordon McKay ;

Krys J. Miller ;

Rabindra N. Patnaik ;

Mark L. Powell ;

Alfred Tonelli ;

C. T. Viswanathan ;

Avraham Yacobi .

Pharmaceutical Research, 2000, 17 (12) :1551-1557

← 1 →